top of page
The Professional Network for Healthcare Experts
FDA approves Roche HER2 companion diagnostics for metastatic gastroesophageal adenocarcinoma
The FDA has expanded approval of two Roche HER2 companion diagnostics to identify patients with metastatic gastroesophageal adenocarcinoma who may be eligible for ZIIHERA treatment.
nuaxia
Sep 242 min read
FDA approves Ziihera-based first-line regimens for HER2-positive advanced gastroesophageal cancers
The approvals introduce zanidatamab-based first-line options for adults with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction or oesophageal adenocarcinoma, with treatment determined by HER2 status.
nuaxia
Aug 262 min read
bottom of page